StockData

NuCana plc (NCNA) stock

NCNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 19, 2026Score 1/30
$0.86−0.07 (-7.45%)

Close on Nov 16, 2026Market cap $3.59MP/E –Yield –

NuCana r&d expenses

Research and development expenses are spending on new products and technology.

NuCana's R&D Expenses for the twelve months ending Dec 31, 2021 was £36.83M, up 42.2% year over year. For fiscal 2025 it was £12.74M, down 29.3% from the year before. Over ten years it grew 8.5% a year on average. The highest annual figure on record is £36.83M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025£12.74M-29.3%
FY2024Dec 31, 2024£18.02M-28.1%
FY2023Dec 31, 2023£25.06M-31.2%
FY2022Dec 31, 2022£36.43M-1.1%
FY2021Dec 31, 2021£36.83M+42.2%
FY2020Dec 31, 2020£25.90M+31.3%
FY2019Dec 31, 2019£19.73M+17.1%
FY2018Dec 31, 2018£16.85M-4.7%
FY2017Dec 31, 2017£17.67M+123.6%
FY2016Dec 31, 2016£7.90M+39.8%
FY2015Dec 31, 2015£5.66M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026£2.25M-64.9%
Q2 FY2025Jun 30, 2025£7.10M-33.2%
Q2 FY2024Jun 30, 2024£6.77M-24.5%
Q2 FY2023Jun 30, 2023£3.96M-53.5%
Q2 FY2022Jun 30, 2022£6.41M-26.4%
Q4 FY2021Dec 31, 2021£10.63M+33.2%
Q3 FY2021Sep 30, 2021£8.97M+46.7%
Q2 FY2021Jun 30, 2021£8.52M+45.4%
Q1 FY2021Mar 31, 2021£8.71M+46.6%
Q4 FY2020Dec 31, 2020£7.98M+54.2%
Q3 FY2020Sep 30, 2020£6.12M+26.3%
Q2 FY2020Jun 30, 2020£5.86M+9.5%
Q1 FY2020Mar 31, 2020£5.94M+36.5%
Q4 FY2019Dec 31, 2019£5.18M+11.3%
Q3 FY2019Sep 30, 2019£4.85M+45.4%
Q2 FY2019Jun 30, 2019£5.36M+3.8%
Q1 FY2019Mar 31, 2019£4.35M+17.4%
Q4 FY2018Dec 31, 2018£4.65M+22.1%
Q3 FY2018Sep 30, 2018£3.33M-67.2%
Q2 FY2018Jun 30, 2018£5.16M+148.3%
Q1 FY2018Mar 31, 2018£3.71M–
Q4 FY2017Dec 31, 2017£3.81M–
Q3 FY2017Sep 30, 2017£10.18M–
Q2 FY2017Jun 30, 2017£2.08M–

More NuCana figures

See a number that looks wrong?